EUROPEAN COMMISSION APPROVES GENZYME'S MYOZYME

A A

Genzyme has received marketing authorization for Myozyme (alglucosidase alfa) in the EU.

Myozyme has been approved for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Pompe disease, a debilitating, progressive and often fatal disorder affecting fewer than 10,000 people worldwide. The product is the first treatment ever approved for Pompe disease and one of the first for an inherited muscle disorder.